Replies to post #271620 on Amarin Corp Plc (AMRN)

[Will Lar]

Marjac - yes, totally understand and agree. Action like this (litigation) can't be taken lightly. It will further distress the sp. It needs to be carefully evaluated for the merits of doing so. What's going on behind the door of Amarin is not known to us, so we can't assume one way or another.

Regardless, I am wondering if we as shareholders can collectively put together a petition to Amarin asking for more clarity on their strategy, and how they would justify their actions for creating "significant shareholder value". They stated on the earning call that "some shareholders" suggested GIA in EU. I don't know who that party is, but as far as I know that many shareholders want a BO. This voice needs to come out strong and loud too.

I can dig a bit further tonight for the news regarding the patent application that I read.

[Will Lar]

Marjac, here is what I dug out.

Among the six invalidated patents, I found a couple of articles discussing the initial PTO rejection or action. SeekingAlpha one has some detailed analysis on '727 and mentioned a response to "Non-Final Office Action" for '715. '727 was submitted together with '728, and granted together on the same date. I included it here even though it is not invalidated.

Admit that I haven't read the patents and analysis in detail.

https://seekingalpha.com/article/600591-amarin-may-16-patent-updates-what-do-they-mean

https://www.reuters.com/article/us-amarin/u-s-patent-office-rejects-amarins-patent-application-idUSTRE81S2EF20120229


FYI, another patent that was rejected and dragged on quite a while before finally granted is the 8,188,146 which carves out the 250-1000mg gelatin capsule of >95% EPA. The reason of rejection wasn't made clear but one article mentioned "Amarin's application was in conflict with another patent that was issued to Mochida, a Japanese drug firm, for its fish-oil drug Epadel". It's always been a mystery to me that Amarin can patent Vascepa after Mochida, but devils can be in the details.
https://www.benzinga.com/news/11/08/1867543/amarin-receives-rejection-on-heart-drug-patent-application


Application # US Patent Patent Granted on Name

13/282,145 8,318,715 11/27/2012 Method of Treating Hypertriglyceridemia. invalidated

12/702,889 8,793,727 10/23/2012 Methods of Treating Hypertriglyceridemia

13/349,153 8,293,728 10/23/2012 Methods of Treating Hypertriglyceridemia invalidated

13/608,775 (followon '153) 8,357,677 1/22/2013 Methods of treating hypertriglyceridemia invalidated

13/610,247 (followon '153) 8,367,652 2/5/2013 Methods of treating hypertriglyceridemia invalidated

13/711,329 8,431,560 4/30/2013 Methods of treating hypertriglyceridemia invalidated

13/776,242 8,518,929 8/27/2013 Methods of treating hypertriglyceridemia invalidated